Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 43: 249-250, 1997;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hedges, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hedges, J. R.
Related Collections
Right arrow Laboratory Management
Right arrow Evidence Based Laboratory Medicine and Test Utilization
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 1999;43:249-250.)
© 1999 American Association for Clinical Chemistry, Inc.

Editorials

Cardiac Enzyme Availability and Hospital Length of Stay

Jerris R. Hedges

Department of Emergency Medicine, School of Medicine, Oregon Health Sciences University, 3181 SW Sam Jackson Park Rd., UHN-52, Portland, OR 97201-3098, Fax 503-494-7689, E-mail Hedgesj@ohsu.edu

In this issue of Clinical Chemistry, Wu and Clive report an association between hospital length of stay (LOS) and the potential availability of CK-MB results (i.e., anticipated turnaround times, given the institutional approach to measurement) at acute-care hospitals in Massachusetts (1). They report a 0.7-day reduction in mean hospital LOS for those patients with an acute myocardial infarction (AMI) and complication(s) who were managed at hospitals performing CK-MB tests more than once or twice per day. They comment that if this reduction in LOS is real, the small increase in institutional cost to provide more-rapid enzyme results would be more than offset by savings related to the shorter hospital LOS.

To put this study into context, one must address several issues: What methodological issues might bias these study results? How are LOS values shortened by the more rapid turnaround times for cardiac enzymes? And why weren't shorter LOSs seen in other DRG categories?

What methodological issues might bias this study? This retrospective observational study design used a claims-based database. Such a billing database may insufficiently permit patient risk stratification for hospital LOS. For example, from such a database alone, we know nothing of patients' socioeconomic status and little about their underlying health status. Both factors may significantly affect clinical disposition decisions. Further, the analysis performed did not address the impact of other factors such as infarct location or procedural interventions (e.g., angioplasty or thrombolysis) on hospital LOS.

There also is significant potential for selection bias at . . . [Full Text of this Article]


References




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
R. H. Christenson, F. S. Apple, D. L. Morgan, G. L. Alonsozana, K. Mascotti, M. Olson, R. T. McCormack, F. H. Wians Jr., J. H. Keffer, and S.-H. Duh
Cardiac troponin I measurement with the ACCESS® immunoassay system: analytical and clinical performance characteristics
Clin. Chem., January 1, 1998; 44(1): 52 - 60.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the American Association for Clinical Chemistry.